Full Text View
Tabular View
No Study Results Posted
Related Studies
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
This study has been completed.
Study NCT00277823   Information provided by Wyeth is now a wholly owned subsidiary of Pfizer

First Received on January 12, 2006.   Last Updated on December 19, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Major Depressive Disorder
Additional conditions recognized in this trial
Depression
Depressive Disorder
Depressive Disorder, Major
More general conditions related to this trial
Behavioral Symptoms
Mental Disorders
Mood Disorders
Interventions listed in this trial
DVS-SR 50 mg
DVS-SR 100 mg
Placebo
Additional drug interventions recognized in this trial
O-desmethylvenlafaxine
More general drug interventions related to this trial
Antidepressive Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Sponsors listed in this trial
Wyeth is now a wholly owned subsidiary of Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services